Caspofungin
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
Caspofungin: From Antifungal Therapy to Gastrin Secretion Abnormality
One-Sentence Summary
Caspofungin is an echinocandin-class antifungal agent; the evidence pack does not specify its Norway-approved indication (drug is currently unmarketed there). The TxGNN model predicts a possible link to Gastrin Secretion Abnormality, but this prediction is supported by zero clinical trials and zero publications, and the accompanying mechanistic analysis explicitly finds no plausible biological pathway connecting the two.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not specified in evidence pack (known drug class: echinocandin antifungal; no approved-indication text provided) |
| Predicted New Indication | Gastrin Secretion Abnormality |
| TxGNN Prediction Score | 99.44% |
| Evidence Level | L5 (model prediction only, no supporting trials/literature) |
| Norway Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, the drug's original_moa field is marked as a data gap. However, the evidence pack's own mechanistic rationale identifies caspofungin as an echinocandin antifungal that inhibits fungal cell wall β-1,3-D-glucan synthase — a fungus-specific enzyme with no human homolog.
No known pharmacological pathway links this mechanism to gastrin secretion regulation (e.g., G-cell function, H+/K+-ATPase, somatostatin signaling, or CCK2 receptor activity). The original indication (systemic antifungal therapy) and the predicted new indication (a gastroenterological/endocrine disorder) share no obvious pathophysiological overlap.
Given the complete absence of clinical trials or literature, and the lack of any interpretable biological mechanism, this prediction is most likely a model artifact or a false-positive association within the knowledge graph rather than a genuine repurposing signal.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
Norway Market Information
No authorizations on record — caspofungin is not currently marketed in Norway (0 licenses).
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: This candidate sits at evidence level L5 (model score only) with no clinical trials, no literature, and no plausible mechanistic link — the evidence pack's own rationale argues against biological plausibility. It does not meet the minimum bar to advance past S0.
To proceed, the following is needed:
- Confirmed MOA and TFDA/regulatory label data (currently blocking safety review per DG001/DG002)
- Independent literature or preclinical evidence establishing a mechanistic link between echinocandin activity and gastrin regulation
- If no such evidence emerges, this candidate should be deprioritized as a likely false-positive prediction
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.